Vienna
Austria
112
2026-10-08
The entities that hold a legal rights for patent applications filed by inventor Schwarz Hans-Peter:
Hans-Peter Schwarz from Vienna, AT has applied for patents for these inventions. The list has both pending applications and granted patents:
STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
#2 | 2026-02-19METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS
#3 | 2025-03-27STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS
#4 | 2023-04-27Stabilized liquid and lyophilized ADAMTS13 formulations
#5 | 2022-05-19METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE
#6 | 2021-12-30METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD
#7 | 2021-09-30IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
#8 | 2021-08-05TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G
#9 | 2021-05-13Removal of serine proteases by treatment with finely divided silicon dioxide
#10 | 2021-02-25METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS
#11 | 2020-12-03Stabilized liquid and lyophilized ADAMTS13 formulations
#12 | 2020-07-09IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES
#13 | 2019-08-15Stabilized liquid and lyophilized ADAMTS13 formulations
#14 | 2019-06-06Removal of serine proteases by treatment with finely divided silicon dioxide
#15 | 2019-05-16Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)
#16 | 2019-05-16TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G
#17 | 2019-03-21Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
#18 | 2018-10-11IgG stimulated remyelination of peripheral nerves
#19 | 2018-07-26Stabilized liquid and lyophilized ADAMTS13 formulations
#20 | 2018-05-03Method to produce an immunoglobulin preparation with improved yield
#21 | 2018-03-01Removal of serine proteases by treatment with finely divided silicon dioxide
#22 | 2017-09-21FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
#23 | 2017-08-03Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs
#24 | 2017-07-13MODELS OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND METHODS OF USE THEREOF
#25 | 2017-06-01Methods of measuring adamts 13 activity
#26 | 2017-04-27Stabilized liquid and lyophilized ADAMTS13 formulations
#27 | 2017-03-09Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
#28 | 2016-12-29Stabilized liquid and lyophilized ADAMTS13 formulations
#29 | 2016-10-27Removal of serine proteases by treatment with finely divided silicon dioxide
#30 | 2016-08-25Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
#31 | 2016-02-04Methods of measuring ADAMTS 13 activity
#32 | 2015-08-20IgG stimulated remyelination of peripheral nerves
#33 | 2015-08-06Recombinant VWF formulations
#34 | 2015-07-23FVIII peptides for immune tolerance induction and immunodiagnostics
#35 | 2014-12-18Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
#36 | 2014-11-13Removal of serine proteases by treatment with finely divided silicon dioxide
#37 | 2014-11-13Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#38 | 2014-11-06TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G
#39 | 2014-10-16Ethanol dependence of alpha1 antitrypsin C-terminal Lys truncation by basic carboxypeptidases
#40 | 2014-09-18Method for producing factor H from a plasma precipitation fraction
#41 | 2014-09-18Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural IgGs
#42 | 2014-09-18Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural IgGs
#43 | 2014-08-21KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A PATIENT'S BLOOD OR PLASMA
#44 | 2014-06-26Stabilized liquid and lyophilized ADAMTS13 formulations
#45 | 2014-06-05Methods of testing effectiveness of a treatment for thromobotic thrombocytopenic purpura by measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor
#46 | 2014-02-06SELECTIVE MEASUREMENT OF ACTIVE HUMAN PROTEASE COAGULATION FACTORS
#47 | 2014-01-30Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
#48 | 2013-11-14Manufacture of factor H (FH) and FH-derivatives from plasma
#49 | 2013-11-07MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
#50 | 2013-09-26Method for testing treatment of ADAMTS13 deficiency
#51 | 2013-08-29Fraction I-IV-1 precipitation of immunoglobins from plasma
#52 | 2013-08-29IgG stimulated remyelination of peripheral nerves
#53 | 2013-08-01Removal of serine proteases by treatment with finely divided silicon dioxide
#54 | 2013-06-13Measurement of autoantibodies at low conductivity with increased sensitivity
#55 | 2013-05-16METHODS FOR THE INACTIVATION OF MIRCROORGANISMS IN BIOLOGICAL FLUIDS, FLOW THROUGH REACTORS AND METHODS OF CONTROLLING THE LIGHT SUM DOSE TO EFFECTIVELY INACTIVATE MICROORGANISMS IN BATCH REACTORS
#56 | 2013-05-09PREPARATIVE PURIFICATION PROCESS FOR HUMAN FURIN
#57 | 2013-04-25Manufacture of factor H (FH) and FH-derivatives from plasma
#58 | 2013-04-25Method to produce an immunoglobulin preparation with improved yield
#59 | 2013-03-28Removal of serine proteases by treatment with finely divided silicon dioxide
#60 | 2013-03-07Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
#61 | 2013-02-28Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
#62 | 2013-02-21Methods of Determining Polydispersity and/or Molecular Weight Distribution of a Polyethylene Glycol Sample
#63 | 2012-12-27Modification-dependent activity assays
#64 | 2012-12-20MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
#65 | 2012-12-20Solid phase-bound elastase-binding assay for the measurement of alpha-antitrypsin activity
#66 | 2012-12-06DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES
#67 | 2012-09-06Method for the determination of polysorbate 80
#68 | 2012-05-31FVIII peptides for immune tolerance induction and immunodiagnostics
#69 | 2012-04-05Transgenic non-human animals expressing human blood clotting factors and uses thereof
#70 | 2012-03-29STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
#71 | 2012-03-29Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
#72 | 2012-02-16Methods for differentiating plasma-derived protein from recombinant protein in a sample
#73 | 2011-12-01Method to produce an immunoglobulin preparation with improved yield
#74 | 2011-12-01Method to produce an immunoglobulin preparation with improved yield
#75 | 2011-12-01Removal of serine proteases by treatment with finely divided silicon dioxide
#76 | 2011-09-22Stabilized liquid and lyophilized ADAMTS13 formulations
#77 | 2011-08-25Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
#78 | 2011-07-21IVIG MODULATION OF CHEMOKINES FOR TREATMENT OF MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, AND PARKINSON'S DISEASE
#79 | 2011-05-19Factor VIII polypeptide having factor VIII:C activity
#80 | 2011-03-24Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
#81 | 2011-03-24Detection of antibody that binds to water soluble polymer-modified polypeptides
#82 | 2011-03-17Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
#83 | 2011-01-27Manufacture of factor H (FH) and FH-derivatives from plasma
#84 | 2010-12-30Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
#85 | 2010-09-09Purification of butyrylcholinesterase using membrane adsorption
#86 | 2010-06-24RECOMBINANT VON WILLEBRAND FACTOR AS MOLECULAR WEIGHT MARKER FOR MASS SPECTROMETRY ANALYSES
#87 | 2010-06-10Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
#88 | 2010-05-27METHODS OF DETERMINING POLYDISPERSITY AND/OR MOLECULAR WEIGHT DISTRIBUTION OF A POLYETHYLENE GLYCOL SAMPLE
#89 | 2010-05-06Models of thrombotic thrombocytopenic purpura and methods of use thereof
#90 | 2009-12-10Preparative purification process for human furin
#91 | 2009-10-01Modified recombinant factor VIII and von Willebrand factor and methods of use
#92 | 2009-09-17Transgenic Non-Human Animals Expressing Human Blood Clotting Factors and Uses Thereof
#93 | 2009-09-03Methods for differentiating plasma-derived protein from recombinant protein in a sample
#94 | 2009-09-03Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro
#95 | 2009-08-13Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#96 | 2009-07-30RECOMBINANT VWF FORMULATIONS
#97 | 2009-06-11IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
#98 | 2009-01-15Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#99 | 2008-07-24Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV
#100 | 2007-11-29Ethanol dependence of alpha1 antitrypsin C-terminal lys truncation by basic carboxypeptidases
96855 ⎘